Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2001-4-26
pubmed:abstractText
Growth hormone secretagogues (GHSs) represent attractive therapeutic alternatives to recombinant growth hormone (GH), given their ability to amplify pulsatile hormone secretion in a relatively physiologic manner. CP-424,391 (391) is a novel, orally active pyrazolinone-piperidine [corrected] GHS. In rat pituitary cell cultures, 391 stimulated GH release with an EC50 = 3 nM. The addition of 391 to rat pituitary cells activated intracellular calcium signaling but did not elevate intracellular cyclic adenosine monophosphate (cAMP). 391 also modulated the effects of GH-releasing hormone and somatostatin on pituitary cell GH-release and intracellular signaling. In nonpituitary cell lines, the ability of 391 to stimulate intracellular signaling was dependent on the expression of recombinant human GHS receptor. Acute administration of 391 to anesthetized rats or to conscious dogs induced pulsatile release of G H in a dose-dependent manner. Plasma insulin-like growth factor-I (IGF-I) was elevated progressively over a 5-d course of daily oral dosing in dogs. Chronic oral administration of 391 augmented body weight gain in rats and dogs. Thus, the peptidomimetic GHS 391 has potential utility for the treatment of clinical conditions that could benefit from systemic augmentation of GH and IGF-I levels.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1355-008X
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
121-32
pubmed:dateRevised
2010-6-24
pubmed:meshHeading
pubmed-meshheading:11322494-Administration, Oral, pubmed-meshheading:11322494-Adrenocorticotropic Hormone, pubmed-meshheading:11322494-Animals, pubmed-meshheading:11322494-Body Weight, pubmed-meshheading:11322494-Calcium, pubmed-meshheading:11322494-Cells, Cultured, pubmed-meshheading:11322494-Dogs, pubmed-meshheading:11322494-Female, pubmed-meshheading:11322494-Growth Hormone, pubmed-meshheading:11322494-Growth Hormone-Releasing Hormone, pubmed-meshheading:11322494-Hydrocortisone, pubmed-meshheading:11322494-Models, Animal, pubmed-meshheading:11322494-Molecular Structure, pubmed-meshheading:11322494-Oligopeptides, pubmed-meshheading:11322494-Peptides, pubmed-meshheading:11322494-Piperidines, pubmed-meshheading:11322494-Pituitary Gland, Anterior, pubmed-meshheading:11322494-Pyrazoles, pubmed-meshheading:11322494-Rats, pubmed-meshheading:11322494-Rats, Sprague-Dawley, pubmed-meshheading:11322494-Rats, Wistar, pubmed-meshheading:11322494-Somatostatin, pubmed-meshheading:11322494-Time Factors
pubmed:year
2001
pubmed:articleTitle
Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.
pubmed:affiliation
Global Research and Development, Pfizer, Inc., Groton, CT 06340, USA [corrected]. lydia_c_pan@groton.pfizer.com
pubmed:publicationType
Journal Article